February 7, 2018
Inside Trading
TradeWins Publishing

Follow Us:



Other Exciting News

The 5 Biggest Income
Producing ETFs
You Should Own Right Now

My name’s Chuck Hughes and I have personally collected weekly cash payouts totaling $9,948,623 over the past 10 years...

We’re talking automatic, non-stop income every week, regardless of market direction!

Grab Your Free Report Now

Find out which 5 ETFs Chuck says are the biggest income producers today...

And start collecting your own weekly payouts of $1,000; $3,000; $15,470 or more as soon as next Friday!

I don’t plan to offer my exclusive cash-producing list free for more than a few days. So please, grab your copy now. I think you’ll be shocked when you see which ETFs made the grade!

Click to download: The Top 5 Income Producing ETFs

Stephen Bigalow

Stephen W. Bigalow possesses over thirty years of investment experience, including eight years as a stockbroker with major Wall Street firms: Kidder Peabody & Company, Cowen & Company and Oppenheimer & Company.

He is an affiliate of the Market Technicians Association, a non-profit association of professional technical analysts (mta.org), and a member of AAPTA - the American Association of Professional Technical Analysts (aapta.us).

Steve has published Profitable Candlestick Trading: Pinpointing Market Opportunities to Maximize Profits and High Profit Candlestick Patterns: Turning Investor Sentiment into High Profits. His implementation of statistical analysis with the Japanese Candlestick methodology has produced some unique successful trading programs.

The Ancient Samurai Secret That Produces 88% Accuracy

My name is Steve Bigalow, and I’ve been trading for nearly 4 decades now.

While I quickly became successful enough to leave my job and trade full-time, I must admit that trading never really made me what I would consider “financially free”...

Or at least not until I learned about an ancient pattern—first discovered by Homna, known as the “God of Markets”...

In the mid-18th century, Homna became the modern equivalent of a billionaire by trading rice futures.

He found that a specific candlestick pattern--based on investor sentiment—slices through all other indicators like a samurai sword.

Of course, candlestick patterns are nothing new and are now known by virtually every trader—and this discovery was only half of the equation.

Learn more about my

Pivotal PROFIT System



Better Business Bureau

Better Business Bureau

Our Author Team
Click on authors name
to learn more


We believe that one of the most exciting – and potentially rewarding – investment ideas is in gene editing. In fact, gene editing is becoming more exciting by the day. It involves the insertion, deletion, or replacement of DNA in a cell or organism. While there are several ways of editing genes, the most exciting technique right now is clustered regularly interspaced short palindromic repeats, or CRISPR, an approach that uses an enzyme found in bacteria to alter DNA. The possibilities for CRISPR gene editing are quite exciting. In fact, with it, there may be a day when genetic diseases can be cured or even prevented altogether. This week, we look at two hot stocks in the gene-editing sector.

Next, Lee Gettess brings us his video newsletter on what he expects from the S&P and bond markets for the coming week.

Stephen Bigalow supplies the next segment where he compares writing covered calls to uncovered puts.

Last, Wendy Kirkland wraps up with her Prime Entry Profits (PEP) Rally Newsletter.


Adrienne LaVigne
TradeWins Publishing


Two Red-Hot Gene-Editing Stocks with 30% Upside

by TradeWins Publishing

We’ve been doing very well with trades.

In fact, we have more wins to take off the table today.

On November 30, 2017, we recommended the following:

  • Editas Medicine (EDIT) at $29. It’s now at $37.25.
  • Intellia Therapeutics (NTLA) at $22. It’s now at $26.26.
  • ARK Genomic Revolution ETF (ARKG) at $24.95. It’s now up to $27.88.

Hold all three.

On December 27, 2017, we recommended the following:

  • Spark Therapeutics (ONCE) at $53. It’s now up to $57.33.
  • BioTelemetry (BEAT) at $30.85. It’s now up to $34.20.
  • Square Inc. (SQ) at $35. It’s now up to $47.15.

Exit half of each of these.

Then, on January 17, 2018, we recommended buying to open the SQ March 2018 43 calls, as they traded at $2.30. They’re now up to $6.35 – a 176% win.

Exit half of this position.

As for new opportunities, one of the hottest stories is still gene editing.

In fact, we’re reiterating a buy on EDIT, and buying into CRISPR Therapeutics (CRSP), too.

We believe that one of the most exciting – and potentially rewarding – investment ideas is in gene editing. In fact, gene editing is becoming more exciting by the day.

Two Red-Hot Gene-Editing Stocks


Lee Gettess' Market Sense

by Lee Gettess

Lee Gettess is a top trader who is excited to bring you his video newsletter. Each week, Lee will share his predictions on what he anticipates from the bond and S&P markets.

Watch Video


Comparing Covered Calls to Uncovered Puts

by Stephen Bigalow

The following is an excerpt from Stephen Bigalow's Pivotal PROFIT System

Complicating the analysis of covered calls is the fact that the uncovered put has the same market risk. Even though these two strategies are opposite (because calls and puts are opposite), the analysis points out an interesting similarity.

The table below summarizes the similarities and differences of the two strategies.

The comparison between the two strategies does involve the same market risk, with some notable differences. For many, the inflexibility of the covered call in cases where the stock price declines below net basis makes uncovered put writing desirable. When the stock price falls, exercise becomes a possibility; but because no stock is owned, the put can be bought to close and replaced with a later-expiring short put. This rolling strategy can be repeated indefinitely.

The greatest risk in writing uncovered puts is that the stock price could fall substantially. For this reason, it makes sense to focus on stocks with two attributes. First, the fundamentals should be very strong, so that price volatility will not be a large factor as long as the short put is open. Second, write puts on stocks with prices lower than average. A stock’s price can only fall so far, so a lower price per share represents lower market risk. Can a stock price fall to zero? In theory, it can. But the true lowest price risk is tangible book value per share; the value of assets minus tangible assets, minus liabilities. A stock can fall below that level, but it would be quite unusual. Most stocks trade above tangible book value, but rarely fall below.

The Ratio Write

Another variation worth considering is an expansion of the covered call, to the ratio write. This is a strategy in which more calls are sold than shares of stock are owned.

Covered Calls to Uncovered Puts


Prime Entry Profits (PEP)

by Wendy Kirkland

Every day Wendy shares her Prime Entry Profits (PEP) Rally Newsletter. The following is her thought for the week, along with what she expects this week in trading.

Thought for the Week: Erase everything from the past that does not serve you, and be grateful it brought you to this place now, and to a new beginning.

In Trading: Indices opened negative and had several swings. The DOW closed at +567, Nasdaq +148, S&P +46.

Be sure to check earnings dates.

AAL- American Airlines – P3
ADBE- Adobe – P3
AIG- American International Group – P3
KO- Coca Cola – P3
CXO- Concho Resources – P3
FB- Facebook – P3
IWM- Russell 2000 – P3

To Learn More Click Here


PLEASE READ: Auto-trading, or any broker or advisor-directed type of trading, is not supported or endorsed by TradeWins. For additional information on auto-trading, you may visit the SEC’s website: All About Auto-Trading, TradeWins does not recommend or refer subscribers to broker-dealers.  You should perform your own due diligence with respect to satisfactory broker-dealers and whether to open a brokerage account. You should always consult with your own professional advisers regarding equities and options on equities trading.

  1. The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the “Services”) is not customized or personalized to any particular risk profile or tolerance.  Nor is the information published by TradeWins Publishing (“TradeWins”) a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products.  The Services are intended to supplemented your own research and analysis.

  2. TradeWins’ Services are not a solicitation or offer to buy or sell any financial products, and the Services are not intended to provide money management advice or services.

  3. Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk. Trading on margin carries a high level of risk, and may not be suitable for all investors.  Other than the refund policy detailed elsewhere, TradeWins does not make any guarantee or other promise as to any results that may be obtained from using the Services.  No person subscribing for the Services (“Subscriber”) should make any investment decision without first consulting his or her own personal financial adviser, broker or consultant. TradeWins disclaims any and all liability in the event anything contained in the Services proves to be inaccurate, incomplete or unreliable, or results in any investment or other loss by a Subscriber.

  4. You should trade or invest only “risk capital” – money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more.

  5. All investments carry risk and all trading decisions made by a person remain the responsibility of that person. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses. Subscribers should fully understand all risks associated with any kind of trading or investing before engaging in such activities.

  6. Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Simulated trading services in general are also designed with the benefit of hindsight, which may not be relevant to actual trading. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading.  TradeWins makes no representations or warranties that any account will or is likely to achieve profits similar to those shown.

  7. No representation is being made that you will achieve profits or the same results as any person providing testimonial.  No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have experienced losses.

  8. The author experiences are not typical.  The author is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position and other factors. Certain Subscribers may modify the author methods, or modify or ignore the rules or risk parameters, and any such actions are taken entirely at the Subscriber’s own election and for the Subscriber’s own risk.